ICPT Projected Dividend Yield
Intercept Pharmaceuticals Inc ( NASDAQ : ICPT )Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases utilizing its proprietary bile acid chemistry. Co.'s marketed product, Ocaliva® (obeticholic acid or OCA), is an farnesoid X receptor agonist approved in the U.S., the European Union and several other jurisdictions for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition, Co. is developing OCA for additional indications, including nonalcoholic steatohepatitis. 20 YEAR PERFORMANCE RESULTS |
ICPT Dividend History Detail ICPT Dividend News ICPT Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |